UNSPSC 51101916: Amopyroquine

This classification denotes an antimalarial agent with the molecular formula C20H20ClN3O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier SV6L22Y9QF, chemically known as 4-((7-chloro-4-quinolyl)amino)-alpha-1-pyrrolidinyl-o-cresol or 4-[(7-chloranylquinolin-4-yl)amino]-2-(pyrrolidin-1-ylmethyl)phenol, but generally known as amopyroquine, which bears US NIH Compound Identifier 25194. European Medicines Agency schedules amopyroquine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05475MIG.

Most nations schedule amopyroquine under HS 29334990 and SITC 51575. As of Q4 2014, AMOPYROQUINE remains the US FDA Preferred Term for this commodity. Amopyroquine bears US NLM identifiers UMLS ID C0051735 and NCI Concept Code C73000. SMILES: C1CCN(C1)CC2=C(C=CC(=C2)NC3=C4C=CC(=CC4=NC=C3)Cl)O.

UNSPSC 51101916 Amopyroquine, a Commodity code, nominally describes a specific antimalarial pharmaceutical, but recent state and local procurement activity under this code shows no direct purchasing of amopyroquine itself. Instead, the code tags a broader range of pharmaceutical and medical supply acquisitions, including naloxone (opioid antagonist), generic multi-source pharmaceuticals, over-the-counter products, and emergency medical supplies. State and local governments buying under this code include county health departments (Seminole County, Florida), state health and human services agencies (Texas HHS Commission), municipal fire departments (City of Tampa), and cooperative purchasing alliances spanning multiple states (Minnesota Multistate Cooperative Purchasing Alliance serving Minnesota and Oregon). The procurement mechanisms range from direct competitive sealed bids for emergency medical consumables through cooperative purchasing arrangements and exploratory requests for information on manufacturer-direct pharmacy programs. Vendors responding to these opportunities must hold FDA compliance certifications, cGMP and Drug Supply Chain Security Act (DSCSA) compliance documentation, appropriate insurance coverage, and demonstrated capacity to serve government wholesaler networks or direct delivery channels.

Recent activity clusters in Florida, Texas, Minnesota, and Oregon. Representative opportunities include Seminole County's IFB 60459723LAS (posted June 30, 2026, due July 26, 2023) for 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries; the City of Tampa's sealed-bid solicitation 26P00145 (posted March 25, 2026, due March 13, 2026) for 169 line items of emergency medical supplies with an estimated contract value of $700,000 and a 5 percent bid discount reserved for certified Small Local Business Enterprises; MMCAP's RFP S1070000015802 (posted January 20, 2026, due March 26, 2026) for generic pharmaceuticals and OTC products through authorized wholesalers with a two-year contract term; and the Texas HHS Commission's RFI HHS0017013 (posted April 3, 2026) exploring direct-to-manufacturer prescription fulfillment models. The code shows active procurement velocity across health departments, emergency services, and state cooperative purchasing vehicles, though the mismatch between the nominal code description (amopyroquine) and actual solicitation content suggests either category misclassification by issuing bodies or vendor tagging inconsistency in the state procurement databases.